MDR1 gene expression in endometrial carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The MDR1 gene encodes P-glycoprotein, a crucial efflux pump involved in multidrug resistance.
• Altered MDR1 gene expression is implicated in various cancers, including endometrial carcinoma.
• Understanding P-glycoprotein expression is vital for predicting treatment response and prognosis in endometrial cancer.

Purpose of the Study:

• To determine the expression levels of the MDR1 gene, specifically P-glycoprotein, in endometrial cancer tissues.
• To investigate the correlation between P-glycoprotein expression and clinicopathological features of endometrial cancer, including age, menopausal status, histological subtype, and tumor grade.

Main Methods:

• Immunohistochemical staining was performed on 26 endometrial carcinoma patient samples using P-glycoprotein dye.
• P-glycoprotein immunoreactivity was quantified as the percentage of stained cells.
• Statistical analyses were conducted to assess correlations between P-glycoprotein expression and clinicopathological parameters.

Main Results:

• Mean P-glycoprotein immunoreactivity in the study group was 17% +/- 25%.
• Endometrioid histology showed higher mean immunoreactivity (21%) compared to clear cell histology (6%).
• A significant negative correlation was observed between patient age and P-glycoprotein immunoreactivity (r = -0.530, P = 0.005).
• Premenopausal patients exhibited significantly higher P-glycoprotein expression (40%) than postmenopausal patients (11%, P = 0.04).

Conclusions:

• P-glycoprotein expression in endometrial cancer is inversely related to advanced age.
• Premenopausal status is associated with significantly higher P-glycoprotein expression.
• These findings highlight the potential role of MDR1 gene expression in the context of endometrial cancer progression and treatment.